10.08.2011 • News

Synthes H1 Profit Rises

Synthes posted higher six-month net earnings of $454.37 million compared with $424.59 million last year. Half-yearly earnings per share improved to €3.83 from €3.58 a year earlier.

Net sales increased to $1.97 billion from $1.80 billion in the comparable period.

First-half 2011 gross profit margin of 82.5% remained strong and was in-line with the previous year of 82.4%, as continued pricing pressures were mitigated by ongoing operational improvements, the company added.

 

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read